Skip to main content
GEMPHARMATECH CO., LTD. logo

GEMPHARMATECH CO., LTD. — Investor Relations & Filings

Ticker · 688046 ISIN · CNE100005964 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 518 across all filing types
Latest filing 2026-05-13 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 688046

About GEMPHARMATECH CO., LTD.

https://en.gempharmatech.com/

GemPharmatech Co., Ltd. is a global biotechnology company specializing in the development and distribution of genetically engineered mouse models (GEMMs) for biomedical research. The company maintains one of the world's largest repositories of mouse strains, including knockout (KO), conditional knockout (cKO), and humanized models designed for oncology, immunology, and metabolic disease studies. Through its Knockout All Project, GemPharmatech aims to create KO and cKO strains for all protein-coding genes in the mouse genome. Beyond model production, the company provides comprehensive preclinical services such as efficacy testing, safety assessment, phenotyping, and customized gene editing using CRISPR/Cas9 technology. Serving pharmaceutical enterprises, biotechnology firms, and academic institutions, GemPharmatech supports drug discovery and fundamental life science research with high-throughput production capabilities and specialized germ-free mouse facilities.

Recent filings

Filing Released Lang Actions
2022年限制性股票激励计划首次授予部分第三个归属期符合归属条件的公告
Share Issue/Capital Change Classification · 85% confidence The document is an official exchange announcement detailing the vesting and issuance of restricted shares under the company’s 2022 stock incentive plan (third vesting period). It specifies share quantities, board and committee approvals, vesting conditions met, and issuance mechanics (source, price, allocation). This represents a targeted new A‐share issuance (capital change) rather than a full financial report, earnings release, or M&A notice. Under our taxonomy, it best fits 'Share Issue/Capital Change' (SHA).
2026-05-13 Chinese
关于调整 2022年限制性股票激励计划授予价格的公告
Share Issue/Capital Change Classification · 75% confidence The document is an official corporate announcement by Jiangsu Jicui Yaokang Biotechnology Co., Ltd. concerning the adjustment of the grant price under its 2022 restricted stock incentive (equity compensation) plan. It is not a financial report or earnings release, nor is it reporting meeting results or voting. It directly relates to a share-based compensation issuance and changes in share capital terms, fitting the “Share Issue/Capital Change (SHA)” category.
2026-05-13 Chinese
第二届董事会第十八次会议决议公告
Board/Management Information Classification · 90% confidence The document is a Board of Directors resolution announcement (‘董事会第十八次会议决议公告’) detailing board meeting procedures, voting results on agenda items (incentive plan adjustments, exercise conditions, and appointment of the financial director). It is an announcement of board/management decisions and changes, fitting the Board/Management Information category.
2026-05-13 Chinese
关于作废部分已授予尚未归属的限制性股票的公告
Share Issue/Capital Change Classification · 85% confidence The document is a formal stock-market announcement by Jiangsu Jiticui Yaokang Biotech Co. detailing the board’s resolution to cancel part of previously granted but unvested restricted stock under its equity incentive plan. This constitutes a change in the company’s share capital structure (cancellation of shares). Under our taxonomy, such notices of share cancellations or other capital changes fall into the Share Issue/Capital Change category (SHA).
2026-05-13 Chinese
董事会薪酬与考核委员会关于2025年股票增值权激励计划第一个行权期行权名单的核查意见
Remuneration Information Classification · 93% confidence The document is a committee opinion from the Board’s Remuneration and Assessment Committee concerning the exercise list of a stock appreciation rights incentive plan. It deals with executive/employee compensation arrangements under the company’s equity incentive plan, which falls squarely under Remuneration Information. Therefore, the appropriate category is DEF 14A (Remuneration Information).
2026-05-13 Chinese
江苏世纪同仁律师事务所关于江苏集萃药康生物科技股份有限公司2022年限制性股票激励计划授予价格调整、首次授予部分第三个归属期归属条件成就暨部分限制性股票作废事项的法律意见书
Regulatory Filings Classification · 75% confidence The document is a standalone legal opinion letter issued by the company’s law firm regarding adjustments, vesting achievements and cancellations under the 2022 restricted stock incentive plan. It does not contain actual financial statements or serve as an earnings/annual/interim report, nor is it a directors’ or management change notice, vote result announcement, or transcript. It is not a proxy solicitation or remuneration disclosure in the format of a DEF 14A, nor is it an Excel financial supplement. Rather, it is a regulatory‐style disclosure/legal compliance attachment that does not fit any of the highly specific categories. Per the fallback rules, such miscellaneous regulatory and compliance filings should be classified as “Regulatory Filings (RNS).”
2026-05-13 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.